AMST earnings analysis
What we found in AMST's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Amesite's latest 10-Q reveals significant revenue growth, with total revenues reaching $285,678 for the nine months ended March 31, 2026, up substantially from $54,700 in the prior year. The company continues to experience net losses, with a net loss of approximately $2,053,000 for the nine months, but has implemented strategies to stabilize its cash position following recent stock offerings.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Total revenue for the nine months ended March 31, 2026 was $285,678, compared to $54,700 in the same period last year.
- Improvement in Losses
- Net loss decreased to approximately $2,053,000 for the nine months ended March 31, 2026, from $2,693,000 in the prior year.
- Increased Cash Position
- Cash, cash equivalents, and restricted cash decreased to $740,711 from $2,433,418 as of March 31, 2026, but the company anticipates cash sufficiency for next operations.
- Lower General and Administrative Expenses
- G&A expenses were approximately $1,676,000 for the nine months ended March 31, 2026, down from $1,866,000 in the prior year.
- Shift to Healthcare Sector
- The company has pivoted focus towards healthcare products, which are expected to drive future growth.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Cash Flow Concerns
- Management raised substantial doubt about the company's ability to continue as a going concern due to cash flow uncertainties.
- Regulatory Compliance Risks
- The company initially struggled to meet Nasdaq's listing requirements, although they regained compliance after recent stock offerings.
- Market Dependency
- The ability to continue generating revenue from partnerships with educational institutions and other sectors remains uncertain.
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · September 29, 2025
- Amesite completed a strategic pivot to healthcare in fiscal 2025 and has commercialized its NurseMagic™ product for both B2C and B2B customers, emphasizing rapid, HIPAA‑compliant deployments. The company highlights…
- 10-Q · February 7, 2025
- Amesite reported revenue of $12,760 for the three months ended December 31, 2024, down from $41,443 in the comparable prior-year quarter, and a net loss of $1,121,637 (loss per share $(0.40)). Management discloses…
- 10-Q · May 10, 2024
- Amesite reported net revenue of $34,261 and GAAP diluted loss per share of $(0.56) for the three months ended March 31, 2024, with net loss of $1,425,912 for the quarter. Revenue plunged versus the prior-year quarter…
- 10-Q · February 14, 2024
- Amesite reported Q2 revenue of $41,443 (three months ended December 31, 2023) versus $237,139 in the year-ago quarter, driving a larger operating loss and continued cash burn. Net loss was $905,611 for the quarter (loss…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AMST makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever